ArticleStem cell research & therapy2025
TLR3-overexpressing umbilical cord mesenchymal stromal cells suppress immune responses to attenuate high-risk corneal transplantation rejection.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Beyond Potency: Emerging Determinants and Optimization Strategies Enhancing Therapeutic Efficacy of Adult Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
- Research Progress on the Regulatory Role of Treg Cells in Inflammatory Eye Diseases.Current issues in molecular biology · 2026Review
- MSCohi-O lenses attenuate corneal transplant rejection via HLA-G5 driven Treg cell expansion.BMC ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe success rates of high-risk corneal transplantation are significantly hindered by immunological rejection. Umbilical cord mesenchymal stem cells (UC-MSCs) have emerged as a potential solution to improve graft outcomes. Toll-like receptors (TLRs) play pivotal roles in the immune response, however, their specific functions in UC-MSC-based treatments for corneal graft rejection requires further investigation.
methodsNew Zealand rabbits that underwent high-risk corneal transplantation were treated with UC-MSC-coated contact lenses (MSCohi-O), while blank lenses and untreated grafts served as controls. Clinical manifestations related to rejection were assessed. RNA-seq was performed on the grafts. GSEA, CIBERSORT, and flow cytometry analyses were performed to investigate the activation of signaling pathways and immune changes. The microarray dataset GSE68610, which contains transcriptome data for normal human UC-MSCs and UC-MSCs treated with cytokines, was analyzed to evaluate TLR expression and identify the key factors involved in the anti-inflammatory effect of UC-MSCs. Overexpression and knockout of TLR3 were performed in UC-MSCs, and the therapeutic effects of TLR3-activated and -inactivated UC-MSCs were compared in a high-risk corneal transplantation model.
resultsMSCohi-O treatment alleviated corneal opacity and edema, inhibited neovascularization, promoted epithelialization, and prolonged the survival time of corneal grafts (all p < 0.05). GSEA revealed that the allograft rejection pathway was upregulated in untreated grafts and downregulated in UC-MSC-treated grafts. Increased numbers of Tregs and decreased numbers of Th17 cells were observed in UC-MSC-treated corneas. An analysis of the GSE68610 dataset revealed that TLR3 expression was upregulated in cytokine-activated UC-MSCs, suggesting that TLR3 is a potential regulator of the immunosuppression function of UC-MSCs. TLR3-overexpressing UC-MSCs exhibited enhanced suppression of rejection in high-risk corneal transplants, whereas TLR3 knockdown diminished these effects.
conclusionsThis study shows that the localized application of UC-MSC-coated contact lenses is capable of inhibiting rejection in high-risk corneal transplantation. TLR3-overexpressing UC-MSCs have enhanced antirejection and immunomodulatory effects. This research could offer a safer and more effective therapeutic strategy to prevent corneal transplant rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.